NCT00517478

Brief Summary

Determine usefulness of thromboelastography (TEG) as a valuable tool in ex-vivo assessing platelet response to aspirin and clopidogrel (dual) treatment and on-treatment platelet reactivity during acute ST segment elevation myocardial infarction (STEMI) in an acute phase during primary PCI (PPCI) and also during recovery been on maintenance medical therapy and to determine the correlation between platelet response to clopidogrel treatment and the outcome of patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2007

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

August 15, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 17, 2007

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
Last Updated

August 17, 2007

Status Verified

July 1, 2007

First QC Date

August 15, 2007

Last Update Submit

August 16, 2007

Conditions

Myocardial InfarctionCardiovascular Disease

Interventions

Blood SamplePROCEDURE

Eligibility Criteria

Age18 Years - 88 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>18 years old STEMI patients admitted to ICCU and in whom the primary PCI is elected as treatment strategy would be enrolled

You may not qualify if:

  • Patient received thrombolytic therapy, chronic renal failure (GFR\<40 ml/min), any known hematological dyscrasia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asaf Harofeh MC

Ẕerifin, Zerifin, 70300, Israel

Location

MeSH Terms

Conditions

Myocardial InfarctionCardiovascular Diseases

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Alex Blatt, MD

    Cardiology Division, Assaf Harofeh Medical Center

    STUDY DIRECTOR

  • Ilia Litovchik, MD

    Cardiology Division, Assaf Harofeh Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alex Blatt, MD

CONTACT

972-8-9779345alexb@asaf.health.gov.il

Ilia Litovchik, MD

CONTACT

972-8-9779347ilitovchik@gmail.com

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

August 15, 2007

First Posted

August 17, 2007

Study Start

August 1, 2007

Study Completion

February 1, 2008

Last Updated

August 17, 2007

Record last verified: 2007-07

Locations

IL(1)